Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × lirilumab × Genitourinary × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 4 Tumor-Agnostic 2 Plasma cell 2 Lymphoid 2 Head & Neck 2 Thoracic 1 Myeloid 1 Genitourinary 1 Dermatologic 1

Conditions

Urinary Bladder Neoplasms 1

Interventions

Docetaxel 359 pembrolizumab 287 Prednisone 261 Gemcitabine 241 Radiotherapy 226 Magnetic Resonance Spectroscopy 226 enzalutamide 223 Nivolumab 223 Cisplatin 182 Abiraterone Acetate 174 Radiosurgery 169 Leuprolide 164 Sunitinib 147 Carboplatin 146 bicalutamide 128 Goserelin 128 Specimen Handling 125 Androgen Antagonists 125 Paclitaxel 118 Ipilimumab 116 Cyclophosphamide 105 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 101 Everolimus 97 apalutamide 92 Bevacizumab 92 cabozantinib 90 Sorafenib 87 abiraterone 83 Radiation 83 atezolizumab 82

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03532451 2024-09-19

PrE0807

PrECOG, LLC.

Phase 1 Completed

43 enrolled 15 charts

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡